<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813627</url>
  </required_header>
  <id_info>
    <org_study_id>BNT000-001</org_study_id>
    <nct_id>NCT04813627</nct_id>
  </id_info>
  <brief_title>Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy</brief_title>
  <official_title>Epidemiological Study to Determine the Prevalence of ctDNA Positivity in Participants With Stage II (High Risk) or Stage III CRC After Surgery With Curative (R0) Intent and Subsequent Adjuvant Chemotherapy With Monitoring of ctDNA During Clinical Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioNTech SE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site epidemiological study designed to monitor circulating tumor DNA (ctDNA)&#xD;
      status in participants with Stage II (high risk)/III colorectal cancer (CRC) following&#xD;
      resection/prior to adjuvant chemotherapy (AdCTx), during the course of AdCTx and for a period&#xD;
      of 21 months thereafter, according to CRC stages and disease characteristics.&#xD;
&#xD;
      This study will identify participants who might be potential candidates for the clinical&#xD;
      trial BNT122-01 (NCT04486378), a study of RO7198457 after completion of standard adjuvant&#xD;
      chemotherapy in this patient population. Based on the eligibility criteria for that trial,&#xD;
      this study will identify participants with confirmed Stage II (high risk)/III CRC that are&#xD;
      positive for ctDNA after resection, and are therefore at high risk of disease recurrence to&#xD;
      enrich the BNT122-01 study cohort. These participants will have the option to enter screening&#xD;
      for BNT122-01 at Screening Visit 2 of that trial if they meet the eligibility criteria of&#xD;
      BNT000-001 during screening. Data from the assessments from BNT000-001 will be carried across&#xD;
      to the BNT122-01 trial where feasible.&#xD;
&#xD;
      Participants receive no therapeutic intervention as part of this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of ctDNA positivity in the post-surgery/pre-AdCTx blood sample</measure>
    <time_frame>4 to 8 weeks after surgery and within 7 days prior up to the day of start of AdCTx</time_frame>
    <description>Blood sample taken post-surgery and pre-adjuvant chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of ctDNA positivity in the first post-AdCTx blood sample</measure>
    <time_frame>14 to 21 days after last AdCTx treatment</time_frame>
    <description>Blood sample taken post-adjuvant chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfer of participants from the BNT000-001 study to the BNT122-01 clinical trial</measure>
    <time_frame>4 weeks following Visit 1 (upon availability of ctDNA positivity status)</time_frame>
    <description>The absolute and relative frequency of participants that will transfer to the BNT122-01 clinical trial from this epidemiological study will be reported.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colorectal Cancer Stage II</condition>
  <condition>Colorectal Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Participants with R0 resected Stage II (high risk) or Stage III CRC</arm_group_label>
    <description>The participants eligible for this epidemiological study are those with completely resected Stage II (high risk)/III CRC (per the American Joint Committee on Cancer (AJCC) 8th revised edition staging system) due to receive standard of care chemotherapy for at least 3 months following surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Regular blood sample collection for ctDNA assessment</intervention_name>
    <description>Blood samples for in vitro testing of ctDNA status will be drawn at study visits every three months</description>
    <arm_group_label>Participants with R0 resected Stage II (high risk) or Stage III CRC</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood and tumor tissue samples collected for ctDNA assessment will be destroyed when&#xD;
           subsequent clinical validity and/or bridging studies to support the validation of ctDNA&#xD;
           assay are completed (where the samples are not exhausted).&#xD;
&#xD;
        -  Remaining biospecimens from a particular participant must be destroyed if the&#xD;
           participant specifically requests that their archival specimens are destroyed upon their&#xD;
           withdrawal from the study.&#xD;
&#xD;
        -  Remaining archival tissue blocks will be returned to the site upon request or no later&#xD;
           than the time of final closure of the study database, whichever occurs first. For&#xD;
           participants who are not eligible for enrollment in study BNT122-01, remaining archival&#xD;
           tissue blocks will be returned to the site no later than 6 months after eligibility&#xD;
           determination.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Stage II (high risk)/III CRC after resection (R0) and that are scheduled&#xD;
        to receive AdCTx will be enrolled in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have given informed consent indicating that they understand the purpose of and&#xD;
             procedures required for the study and are willing to participate in the study.&#xD;
&#xD;
          -  Age ≥ 18 years old at time of signing the informed consent form.&#xD;
&#xD;
          -  Ability to comply with the study protocol, in the investigator's judgment.&#xD;
&#xD;
          -  Must have Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon&#xD;
             cancer per AJCC 2017 that has been surgically totally resected (R0 confirmed by&#xD;
             pathology report). Stage II (high risk) colon cancer is defined as (any of):&#xD;
&#xD;
               -  T4&#xD;
&#xD;
               -  Grade ≥ 3&#xD;
&#xD;
               -  Clinical presentation with bowel obstruction or perforation&#xD;
&#xD;
               -  Histological signs of vascular, lymphatic or perineural invasion&#xD;
&#xD;
               -  &lt; 12 nodes examined&#xD;
&#xD;
          -  Adequate tumor material in formalin-fixed paraffin embedded (FFPE) blocks or as&#xD;
             sectioned tissue (only upon approval by sponsor) must be available, preferably from&#xD;
             resection. The specimen should be submitted along with an associated pathology report.&#xD;
             Multiple samples may be provided as available, but priority should be given to tissue&#xD;
             with the highest tumor content and lowest necrotic area.&#xD;
&#xD;
          -  Intention to receive a standard of care adjuvant chemotherapy (AdCTx) within 8 weeks&#xD;
             post-surgery, and be scheduled for at least 3 months of treatment according to the&#xD;
             treating physician or investigator.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          -  Adequate end-organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Induction of neoadjuvant systemic therapy prior to resection of CRC.&#xD;
&#xD;
          -  Prior systemic investigational therapy.&#xD;
&#xD;
          -  Positive serology for hepatitis B (unless immune due to vaccination or resolved&#xD;
             natural infection or unless passive immunization due to immunoglobulin therapy):&#xD;
&#xD;
               -  Positive test for antibodies to hepatitis B core antigens (anti HBc) and&#xD;
&#xD;
               -  Negative test for antibodies to hepatitis B surface antigens (anti HBs).&#xD;
&#xD;
          -  Active hepatitis C virus (HCV) infection; participants who have completed curative&#xD;
             antiviral treatment with HCV viral load below the limit of quantification by&#xD;
             polymerase chain reaction (PCR) are allowed.&#xD;
&#xD;
          -  Participant has a history of human immunodeficiency virus (HIV) antibody positivity,&#xD;
             or tests positive for HIV at screening.&#xD;
&#xD;
          -  Residual tumor classification following surgery other than R0 (microscopic&#xD;
             margin-negative resection).&#xD;
&#xD;
          -  Diagnosis with disease other than Stage II/Stage III rectal cancer or Stage II (high&#xD;
             risk)/Stage III colon cancer per AJCC 2017 following surgery.&#xD;
&#xD;
          -  Participant has not started standard of care AdCTx within 8 weeks post-surgery.&#xD;
&#xD;
          -  Participant has received less than 3 months of AdCTx treatment.&#xD;
&#xD;
          -  Inadequate tumor material (either quality and quantity) to support circulating tumor&#xD;
             DNA (ctDNA) analysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BioNTech Responsible Person</last_name>
    <role>Study Director</role>
    <affiliation>BioNTech SE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BioNTech clinical trials patient information</last_name>
    <phone>+49 6131 9084</phone>
    <phone_ext>1919</phone_ext>
    <email>patients@biontech.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BioNTech clinical trial information desk</last_name>
    <phone>+49 6131 9084</phone>
    <phone_ext>0</phone_ext>
    <email>info@biontech.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marin Cancer Care</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists Of Central Illinois Sc (CcsDcei)</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc.</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rockwood Cancer Treatment Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centres Hospitaliers Jolimont</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique et Maternite Sainte-Elisabeth (CMSE)</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Pierre d'ottignies (CSPO)</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis (AZ) Glorieux</name>
      <address>
        <city>Ronse</city>
        <zip>9600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional, CHR</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. med. B. Heinrich, Prof. M. Bangerter MD</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Center Donauwoerth and Dachau</name>
      <address>
        <city>Donauwoerth</city>
        <zip>86609</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum fuer Haematologie und Onkologie Bethanien</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IOR- Instituto Quiron Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General De Granollers</name>
      <address>
        <city>Granollers</city>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Orense</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

